FORT WORTH, Texas, Jan. 19 /PRNewswire-FirstCall/ -- Wound Management Technologies, Inc., a rapidly growing provider of specialty medical products, announced today that its subsidiary Wound Care Innovations was highlighted as part of a presentation exhibited at the SuperBones East conference in Nassau, Bahamas, on January 14-17. The SuperBones Conference has a great reputation for high quality educational lectures and workshops and places top national speakers at the podium. It was designed to provide a specialty education format that includes vital industry topics and techniques to medical practitioners that specialize in treatment of the lower extremities.
Cathy Bradshaw, President of Wound Care Innovations, was quoted as saying "As noted in Dr. Rothenberg's presentation, 85% of all LEA (lower extremity amputations) are preceded by non-healing ulcerations. Our product has been shown to successfully address these diabetic wounds."
WNDM also announced the completion of sales training for another group of HIRA (Health Industry Representatives Association) reps who will market and sell CellerateRX throughout the United States. "HIRA brings an additional avenue for market penetration for us throughout the United States," added Bradshaw. "Our product successfully addresses a complex and costly segment of healthcare."
For Wound Management Technologies Shareholder Information please call 954-357-0614 or go to http://www.woundmanagementtechnologies.com
"Safe Harbor" Statement: Under The Private Securities Litigation Reform Act of 1995:
The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are "forward-looking statements," within the meaning of the Private Securities Litigation Reform Act of 1995. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. This document may contain forward-looking statements concerning the Company's operations, current and future performance and financial condition. These items involve risks and uncertainties such as product demand, market and customer acceptance, the effect of economic conditions, competition, pricing, the ability to consummate and integrate acquisitions, and other risks and uncertainties detailed in the Company's SEC filings. The Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events.
Wound Management Technologies, Inc.
